Topics

Ankylosing Spondylitis

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Online Consultation System Benefits Rheumatic Disease Management

The SSDM series of applications is cost-effective for patients of rheumatologists.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

FDA Approval of Biosimilar Cyltezo for Multiple Indications

Cyltezo subcutaneous injection has been approved by the FDA.

Sign Up for Free e-newsletters